Search 33,000+ CME courses
Back

RedMedEd, Partners for Advancing Clinical Education

  • Immune Checkpoint Inhibitors
  • Immunoconjugates
  • Urinary Bladder Neoplasms

Novel Therapies for Perioperative Management of Muscle-Invasive Bladder Cancer

As the molecular events responsible for invasive bladder cancer have become better understood in recent years, novel immunotherapies have emerged as a new therapeutic option. In particular, the role of antibody-drug conjugates (ADCs) and immune checkpoint inhibitors (ICIs) has expanded in the perioperative management of muscle-invasive bladder cancer (MIBC). These newer immunotherapies have been shown to improve outcomes, but they are associated with unique, sometimes life-threatening, adverse events (AEs). This activity reviews the expanding use of ADCs and ICIs in MIBC (including the mechanisms underlying their effectiveness), provides updates on evolving treatment guidelines and management strategies for common treatment-related AEs, and looks at new and emerging clinical trial data.

Credit & MOC Details

Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.

Credit types

AAPA Category 1 Credit™Up to 0.75 creditsAMA PRA Category 1 Credit™Up to 0.75 creditsNursingUp to 0.75 credits

MOC types

ABIM — Medical KnowledgeUp to 0.75 points

FDA REMS

No

Qualifies for MIPS

No

Target Specialties

Pricing

Free

Reported to ACCME by the provider

  • Enduring / On-demand
  • Credit · Up to 0.75 credits
  • MOC · Up to 0.75 points
  • Commercial Support
  • Released
    Jun 12, 2026
  • Last day to claim credit
    Jun 13, 2027 8 months left

Related courses

See all

Other providers’ courses on the same topic

More from Partners for Advancing Clinical Education

See all

This provider’s courses closest to this one